The 2023-2028 World Outlook for Intravenous Immunoglobulins
In this report we define the sales of intravenous immunoglobulins as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include ADMA Biologics, Baxter International, Bayer Healthcare, BDI Pharma, Beijing Tiantan Biological Products Company, Bharat Serums and Vaccines, Bio Products Laboratory, China Biologic Products, CSL, Grifols, Guizhou Taibang Biological Products Company, Hualan Biological Engineering, Kedrion, LFB, Octapharma, OMRIX Biopharmaceuticals, Sanquin Plasma Products B.V., Shanghai RAAS Blood Products Company, and Shire. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication’s release in 2022).
Additional information
Publisher | ICON Group International, Inc. (10 May 2022) |
---|---|
Language | English |
Paperback | 288 pages |
Dimensions | 21.59 x 1.65 x 27.94 cm |
Reviews
There are no reviews yet.